Andres Y. Maldonado

Stock Analyst at H.C. Wainwright

(4.91)
# 245
Out of 4,988 analysts
334
Total ratings
52.1%
Success rate
34.9%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Andres Y. Maldonado

Corbus Pharmaceuticals Holdings
Sep 15, 2026
Reiterated: Buy
Price Target: $35
Current: $7.48
Upside: +367.91%
Scholar Rock Holding
Sep 15, 2026
Reiterated: Buy
Price Target: $65$70
Current: $46.65
Upside: +50.05%
Verastem
Sep 14, 2026
Reiterated: Buy
Price Target: $18
Current: $7.44
Upside: +141.94%
Immunome
Sep 11, 2026
Reiterated: Buy
Price Target: $40
Current: $23.97
Upside: +66.88%
enGene Therapeutics
Sep 9, 2026
Reiterated: Buy
Price Target: $4
Current: $1.91
Upside: +109.42%
TScan Therapeutics
Sep 9, 2026
Downgraded: Hold
Price Target: $7$1
Current: $0.3119
Upside: +220.62%
Immuneering
Aug 27, 2026
Reiterated: Buy
Price Target: $14
Current: $4.48
Upside: +212.50%
NovaBridge Biosciences
Aug 20, 2026
Reiterated: Buy
Price Target: $9
Current: $1.60
Upside: +462.50%
Candel Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $23
Current: $10.85
Upside: +111.98%
Monopar Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $125
Current: $96.47
Upside: +29.57%
Reiterated: Buy
Price Target: $50
Current: $15.34
Upside: +225.95%
Reiterated: Buy
Price Target: $24$18
Current: $6.44
Upside: +179.50%
Reiterated: Buy
Price Target: $20$22
Current: $14.77
Upside: +48.95%
Reiterated: Buy
Price Target: $27
Current: $3.55
Upside: +660.56%
Reiterated: Buy
Price Target: $12
Current: $4.12
Upside: +191.26%
Reiterated: Buy
Price Target: $100
Current: $74.62
Upside: +34.01%
Reiterated: Buy
Price Target: $13
Current: $4.14
Upside: +214.01%
Reiterated: Buy
Price Target: $10
Current: $3.11
Upside: +221.54%
Reiterated: Buy
Price Target: $40$38
Current: $17.62
Upside: +115.66%
Reiterated: Buy
Price Target: $15
Current: $8.48
Upside: +76.89%
Reiterated: Buy
Price Target: $20
Current: $11.19
Upside: +78.73%
Reiterated: Buy
Price Target: $10$4
Current: $0.965
Upside: +314.51%
Reiterated: Buy
Price Target: $4
Current: $4.89
Upside: n/a